ArticleJournal of the National Cancer Institute2016

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Shiv K Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.